A Study To Demonstrate The Bioequivalence Of Rosiglitazone XR (BRL-049653) 8mgs XR Manufactured At Two Different Sites.

An Open-Label, Randomized, Two-Period Crossover Study to Demonstrate the Bioequivalence of a Tablet Formulation of Rosiglitazone XR (BRL-049653) 8mg Manufactured at Two Different Sites in Healthy Volunteers in Fasting Conditions

The present pharmacokinetic study is designed to compare bioavailability and assess bioequivalence of two Rosiglitazone XR formulations produced at two different sites.Both formulations will be tested in fasting healthy volunteers

Inclusion Criteria:

• Healthy male or female aged 18-55 years.
• BMI between 19 - 30 kg/m2

Exclusion criteria:

• Liver function tests above the upper limit
• Excessive alcohol consumption history
• History of Cigarette smoking
• Positive HIV, Hep B or C test
• Positive pregnancy test
• History of heparin sensitivity
• History of glucose intolerance